Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-ΚB signaling in vitro

Journal of Translational Medicine

Volumn 14, Issue 1, 2016, Pages

  Liu, Hong ^a,b   Zhang, Guonan ^b   Huang, Jianming ^b   Ma, Shiqi ^b   Mi, Kun ^b   Cheng, Jia ^b   Zhu, Yi ^b   Zha, Xiao ^b   Huang, Wei ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN CANCER HOSPITAL   (China)

Author keywords

Atractylenolide I; Epithelial ovarian cancer; Immunosuppressive cytokines; Indoleamine 2,3 dioxygenase; MyD88 NF B signaling; TLR4 MD 2 complex

Indexed keywords

ATRACTYLENOLIDE I; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE 1; INTERLEUKIN 17; INTERLEUKIN 6; KYNURENINE; MYELOID DIFFERENTIATION FACTOR 88; OXYGENASE; PROTEIN KINASE B; PROTEIN MD 2; SESQUITERPENE LACTONE DERIVATIVE; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN; CYTOKINE; INDOLEAMINE 2,3 DIOXYGENASE; LACTONE; SESQUITERPENE;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; NATURAL KILLER CELL; OVARIAN CANCER CELL LINE; OVARY CANCER; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; CELL PROLIFERATION; CYTOTOXICITY; DRUG EFFECTS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOSUPPRESSION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; LACTONES; LYMPHOCYTE ANTIGEN 96; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SESQUITERPENES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 4;

EID: 84965034954     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-016-0845-5     Document Type: Article

References (46)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29.
2. Latha TS, Panati K, Gowd DS, Reddy MC, Lomada D. Ovarian cancer biology and immunotherapy. Int Rev Immunol. 2014;33:428-40.
3. Lavoué V, Thédrez A, Levêque J, Foucher F, Henno S, Jauffret V, Belaud-Rotureau MA, Catros V. Cabillic F Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med. 2013;11:147. doi: 10.1186/1479-5876-11-147.
4. Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol. 2010;117:366-72.
5. Chen R, Alvero AB, Silasi DA, Steffensen KD, Mor G. Cancers take their toll-the function and regulation of toll-like receptors in cancer cells. Oncogene. 2008;27:225-33.
6. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene. 2008;27:218-24.
7. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC, Xiong H. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 2005;65:5009-14.
8. Zhou M, McFarland-Mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF. Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother. 2009;58:1375-85.
9. Awasthi S. Toll-like receptor-4 modulation for cancer immunotherapy. Front Immunol. 2014;5:328.
10. d'Adhemar CJ, Spillane CD, Gallagher MF, Bates M, Costello KM, Barry-O'Crowley J, et al. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer. PLoS One. 2014;9:e100816.
11. Zhu Y, Huang JM, Zhang GN, Zha X, Deng BF. Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells. J Transl Med. 2012;10:77. doi: 10.1186/1479-5876-10-77.
12. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature. 2009;458:1191-5.
13. Gay NJ, Symmons MF, Gangloff M, Bryant CE. Assembly andlocalization of toll-like receptor signalling complexes. Nat Rev Immunol. 2014;14:546-58.
14. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M. MD-2, a molecule that confers lipopolysaccharide responsiveness on toll-like receptor 4. J Exp Med. 1999;189:1777-82.
15. Carmody RJ, Chen YH. Nuclear factor-kappaB: activation and regulation during toll-like receptor signaling. Cell Mol Immunol. 2007;4:31-41.
16. Nishio H, Yaguchi T, Sugiyama J, Sumimoto H, Umezawa K, Iwata T, Susumu N, Fujii T, Kawamura N, Kobayashi A, Park J, Aoki D, Kawakami Y. Immunosuppression through constitutively activated NF-ΚB signalling in human ovarian cancer and its reversal by an NF-ΚB inhibitor. Br J Cancer. 2014;110:2965-74.
17. Carr TM, Adair SJ, Fink MJ, Hogan KT. Immunological profiling of a panel of human ovarian cancer cell lines. Cancer Immunol Immunother. 2008;57:31-42.
18. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res. 2011;17:6083-96.
19. Berger S, Siegert A, Denkert C, Köbel M, Hauptmann S. Interleukin-10 in serous ovarian carcinoma cell lines. Cancer Immunol Immunother. 2001;50:328-33.
20. Rabinovich A, Medina L, Piura B, Huleihel M. Expression of IL-10 in human normal and cancerous ovarian tissues and cells. Eur Cytokine Netw. 2010;21:122-8.
21. Santin AD, Ioli GR, Hiserodt JC, Rose GS, Graf MR, Tocco LM, Lander JK, Eck LM, Burger RA, DiSaia PJ, et al. Development and characterization of an IL-4-secreting human ovarian carcinoma cell line. Gynecol Oncol. 1995;58:230-9.
22. Duncan TJ, Al-Attar A, Rolland P, Scott IV, Deen S, Liu DT, Spendlove I, Durrant LG. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res. 2008;14:3030-5.
23. Kato T, Furumoto H, Ogura T, Onishi Y, Irahara M, Yamano S, Kamada M, Aono T. Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun. 2001;282:735-8.
24. Francis-Thickpenny KM, Richardson DM, van Ee CC, Love DR, Winship IM, Baguley BC, Chenevix-Trench G, Shelling AN. Analysis of the TGF beta functional pathway in epithelial ovarian carcinoma. Br J Cancer. 2001;85:687-91.
25. Kryczek I, Gryboś M, Karabon L, Klimczak A, Lange A. IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity. Br J Cancer. 2000;82:621-8.
26. Hirashima Y, Kobayashi H, Suzuki M, Tanaka Y, Kanayama N, Terao T. Transforming growth factor-beta1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells. J Biol Chem. 2003;278:26793-802.
27. Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, Kawaguchi R, Isonishi S, Tanaka T, Urashima M. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res. 2005;11:6030-9.
28. Wang D, Saga Y, Mizukami H, Sato N, Nonaka H, Fujiwara H, Takei Y, Machida S, Takikawa O, Ozawa K, Suzuki M. Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits NK cell function, as a useful target for ovarian cancer therapy. Int J Oncol. 2012;40:929-34.
29. Tanizaki Y, Kobayashi A, Toujima S, Shiro M, Mizoguchi M, Mabuchi Y, Yagi S, Minami S, Takikawa O, Ino K. Indoleamine 2,3-dioxygenase promotes peritoneal metastasis ofovarian cancer by inducing an immunosuppressive environment. Cancer Sci. 2014;105:966-73.
30. Johnson B, Osada T, Clay T, Lyerly H, Morse M. Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression. Curr Mol Med. 2009;9:702-7.
31. Endo K, Taguchi T, Taguchi F, Hikino H, Yamahara J, Fujimura H. Antiinflammatory principles of Atractylodes rhizomes. Chem Pharm Bull. 1979;27:2954-8.
32. Ji G, Chen R, Zheng J. Atractylenolide I inhibits lipopolysaccharide-induced inflammatory responses via mitogen-activated protein kinase pathways in RAW264.7 cells. Immunopharmacol Immunotoxicol. 2014;36:420-5.
33. Huang JM, Zhang GN, Shi Y, Zha X, Zhu Y, Wang MM, Lin Q, Wang W, Lu HY, Ma SQ, Cheng J, Deng BF. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway. Sci Rep. 2014;4:3840.
34. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, Enkhbayar P, Matsushima N, Lee H, Yoo OJ, Lee JO. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell. 2007;130:906-17.
35. Deguchi A, Tomita T, Ohto U, Takemura K, Kitao A, Akashi-Takamura S, Miyake K, Maru Y. Eritoran inhibits S100A8-mediated TLR4/MD-2 activation and tumor growth by changing the immune microenvironment. Oncogene. 2015. doi: 10.1038/onc.2015.211.
36. Toutirais O, Chartier P, Dubois D, Bouet F, Lévêque J, Catros-Quemener V, Genetet N. Constitutive expression of TGF-beta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. Eur Cytokine Netw. 2003;14:246-55.
37. Wei H, Liu P, Swisher E, Yip YY, Tse JH, Agnew K, Hellström KE, Hellström I. Silencing of the TGF-β1 gene increases the immunogenicity of cells from human ovarian carcinoma. J Immunother. 2012;35:267-75.
38. Ziogas AC, Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Terpos E, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, Antsaklis A, Dimopoulos MA, Bamias A. VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. Int J Cancer. 2012;130:857-64.
39. Johnson BF, Clay TM, Hobeika AC, Lyerly HK, Morse MA. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther. 2007;7:449-60.
40. Stahl HF, Fauti T, Ullrich N, Bopp T, Kubach J, Rust W, Labhart P, Alexiadis V, Becker C, Hafner M, Weith A, Lenter MC, Jonuleit H, Schmitt E, Mennerich D. miR-155 inhibition sensitizes CD4+ Th cells for TREG mediated suppression. PLoS One. 2009;4:e7158.
41. Tsai CY, Allie SR, Zhang W, Usherwood EJ. MicroRNA miR-155 affects antiviral effector and effector memory CD8 T cell differentiation. J Virol. 2013;87:2348-51.
42. Kohlhaas S, Garden OA, Scudamore C, Turner M, Okkenhaug K, Vigorito E. Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol. 2009;182:2578-82.
43. Salaun B, Yamamoto T, Badran B, Tsunetsugu-Yokota Y, Roux A, Baitsch L, Rouas R, Fayyad-Kazan H, Baumgaertner P, Devevre E, Ramesh A, Braun M, Speiser D, Autran B, Martiat P, Appay V, Romero P. Differentiation associated regulation of microRNA expression in vivo in human CD8+ T cell subsets. J Transl Med. 2011;9:44.
44. Zhou J, Ye F, Chen H, Lv W, Gan N. The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med Res. 2007;35:290-300.
45. Ino K. Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer. Curr Opin Obstet Gynecol. 2011;23:13-8.
46. + T cells. Mol Cell Biochem. 2008;309:1-7.